Kodiak Announces Positive Phase 3 Trial Results and Ongoing Development for Zenkuda, Tabirafusp-Ted, and KSI-101

Kodiak Sciences reported positive top-line results from three Phase 3 clinical trials, highlighting the potential of its late-stage pipeline assets to address significant unmet needs in wet AMD and retinal inflammation. The data solidifies the company's position in the retina landscape and supports multiple upcoming regulatory submissions.